Prostate-specific antigen testing in general practice: A survey among 325 general practitioners in Denmark

Objectives Prostate-specific antigen (PSA) is a well-known and -utilized tumor marker for prostate cancer. Elevated PSA values are not specific for prostate cancer as they may be caused by other benign conditions. PSA testing is widely used by urologists and non-urologists. Interpretation of test results is difficult but important. Referral of patients for further work-up on suspicion of prostate diseases is mainly done by general practitioners (GPs). As the GP remains the gatekeeper between the patient and the urologist in terms of diagnosing prostate diseases, basic knowledge of PSA testing is crucial. The purpose of this study was to evaluate the basic use and knowledge of PSA testing and to give an estimate of the need for further education in PSA testing amongst GPs in our area. Material and methods A questionnaire regarding PSA testing and associated needs for education was mailed to all GPs in the Northern County of Denmark. Non-respondents were contacted by mail. Results Of the contacted GPs, 90% responded. Only 28% of GPs measured PSA in all males complaining of lower urinary tract symptoms (LUTS). Of patients seen as part of a general health check-up, PSA testing was done in 10%. The median PSA value for referral to urologists for further work-up was 5 ng/ml, but the decision was influenced by PSA value (79%), age (65%) and findings on digital rectal examination (DRE) (87%). Opportunistic screening for prostate cancer was done by 14% of GPs. Of the GPs who responded, 24% stated that they did not need any further education regarding PSA testing. Conclusions The results of this study demonstrate that PSA testing is not standardized in our area. GPs do not test patients on the basis of recommendations provided by national or international societies. PSA testing is not used as a standard test in men with LUTS, and patients are not referred to urologists at a sufficiently low PSA level to improve the early diagnosis and work-up of patients with suspected prostate cancer. However, the decision of many GPs to refer patients to urologists for further work-up is influenced by the findings of a DRE, the age of the patient and the PSA value itself. Further education regarding PSA testing amongst GPs in our area would seem to be appropriate.

[1]  L. Weissbach,et al.  Systematic development of a guideline for early detection of prostate cancer: the German way in the evidence gap. , 2004, European urology.

[2]  Ian M Thompson,et al.  Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker , 2004, Cancer.

[3]  C. Pinnock,et al.  Promoting better use of the PSA test in general practice: randomized controlled trial of educational strategies based on outreach visits and mailout. , 2003, Family practice.

[4]  Etienne Mullet,et al.  Why do Primary Care Physicians in the United States and France Order Prostate-Specific Antigen Tests for Asymptomatic Patients? , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.

[5]  S. Brewster,et al.  Opportunities and outcomes in early prostate cancer: a commentary on policy, patient perspectives, trials and strategies , 2003, BJU international.

[6]  Kathleen N Lohr,et al.  Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force , 2002, Annals of Internal Medicine.

[7]  T. Miki,et al.  [Natural history of prostate cancer]. , 2002, Nihon rinsho. Japanese journal of clinical medicine.

[8]  J. Oesterling,et al.  Prostate specific antigen: a decade of discovery--what we have learned and where we are going. , 1999, The Journal of urology.

[9]  T. Brett.  An analysis of digital rectal examination and serum-prostate-specific antigen in the early detection of prostate cancer in general practice. , 1998, Family practice.

[10]  J. Oesterling,et al.  Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists. , 1998, The American journal of medicine.

[11]  V. Goel,et al.  Why don't family physicians follow clinical practice guidelines for cancer screening? Family Physician Study Group, Sociobehavioral Cancer Research Network, National Cancer Institute of Canada. , 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[12]  J. Oesterling,et al.  The clinical usefulness of prostate specific antigen: update 1994. , 1994, The Journal of urology.

[13]  J. Oesterling,et al.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.